New Psoriasis Drug Showed Better Skin Clearance Results
Adults with plaque psoriasis may soon have a more effective oral treatment option based on new phase 3 trial findings.
Updated on Oct. 13, 2026 in Arthritis
Live Poll
Would you trust a new medication more than an existing one if clinical trials showed higher effectiveness?
In the phase 3 LATITUDE Atlas study, the oral medication zasocitinib demonstrated superior skin clearance outcomes for plaque psoriasis compared to deucravacitinib. The findings offer a potential new treatment pathway for patients managing moderate to severe symptoms.
Why it matters
The study provides evidence that higher potency oral therapies may offer significant improvements in skin clearance for patients. These findings help clarify the evolving options for those who require more effective long-term management of their condition.
In a 16-week phase 3 trial of 604 participants, 36.5% of those taking 30 mg of zasocitinib achieved complete skin clearance, compared to 13.9% of those on 6 mg of deucravacitinib. Additionally, 62.5% of the zasocitinib group reached PASI 90, versus 34% of the comparator group.
The players
Henry Ford Health
A healthcare provider and research system hosting the principal investigator for the LATITUDE Atlas study.
The details
The LATITUDE Atlas study evaluated the efficacy of daily oral dosing in targeting inflammation associated with plaque psoriasis. Researchers monitored primary endpoints including PASI scores and Physician Global Assessment (PGA) levels to track the reduction in skin lesions. While zasocitinib demonstrated higher clearance rates, the safety profile remained consistent with other treatments in the class, with common side effects including acne, nasopharyngitis, and upper respiratory infection.
Timeline
The treatment duration for all study participants lasted 16 weeks.
Data from the phase 3 study were presented on October 13, 2026.
Health Landscape
The LATITUDE Atlas study represents a major shift in how researchers evaluate comparative efficacy for oral plaque psoriasis treatments. It builds upon current clinical standards by testing whether newer, more potent molecules can surpass established oral therapies.
If you are currently managing moderate to severe plaque psoriasis, these findings suggest that oral treatment options continue to evolve toward higher efficacy rates. It is worth discussing with your doctor how new research developments might eventually influence the range of available therapies for your specific condition.
The takeaway
Zasocitinib demonstrated higher rates of skin clearance compared to deucravacitinib in this latest phase 3 clinical assessment. Patients should continue to track symptom progression and review new therapeutic options with a rheumatologist or dermatologist.
Further reading
For more information on managing inflammatory conditions, visit the Arthritis section.
Live Poll
Would you trust a new medication more than an existing one if clinical trials showed higher effectiveness?
